Dr Javad Aman | President and Chief Scientific Officer
Integrated Biotherapeutics

Dr Javad Aman, President and Chief Scientific Officer, Integrated Biotherapeutics

Dr. M. Javad Aman is a molecular immunologist with over 20 years of experience in the field of vaccine and immunotherapeutics development for infectious diseases. Dr. Aman received his Ph.D. at the University of Mainz in Germany and completed two post-doctoral fellowships at NIH and University of Virginia with a focus on regulation of B and T cell responses. He then moved to the US Army Medical Research Institute of Infectious Diseases (USAMRIID), where he focused on development of vaccines and immunotherapeutics for filoviruses as well as several bacterial toxins. His filovirus research team is currently focused on developing broadly neutralizing antibodies against multiple Ebola and Marburg viruses. Dr. Aman has also been on the forefront of research on staphylococcal toxins and developed several vaccine candidates for this pathogen. In 2007, he founded the research-based company Integrated Biotherapeutics Inc. (IBT) and grew the company to its current size of 30 employees focused on development of vaccines and antibody therapeutics for emerging infectious disease.


Day 1 Antibody Congress @ 09:00

PLENARY KEYNOTE: Attacking Ebola with a Trojan Horse: A dual bispecific antibody cocktail targeting Ebola’s Niemann-Pick C1 (NPC1) binding protein

  • Overcoming monoclonal antibody approach for Ebola, which has limitations in targeting multiple viruses in same family
  • Capitalizing on filovirus biology: how understanding the virus pathogenicity mechanism helps in engineering a smart bispecific
  • Overcoming the “invisibility cloak” – getting inside the lysosomes on the back of Ebola with a dual bi-specific, making it the architect of its own destruction

back to speakers